Globus Medical Inc. Class A Common Stock vs Zeta Global Holdings Corp — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Zeta Global Holdings Corp trades at $31.63 (market cap $8.48B). The key difference: Globus Medical Inc. Class A Common Stock is the larger of the two by market cap, and Zeta Global Holdings Corp is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Zeta Global Holdings Corp for 19 Days on average.
| GMED | ZETA | |
|---|---|---|
Market Cap | $10.25B | $8.48B |
Volume | 1,108,124 | 4,868,041 |
Sector | Health | Technology |
52-Week High | $96.82 | $33.80 |
52-Week Low | $58.33 | $14.55 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $9.76B | $8.37B |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Zeta Global (ZETA) trades at $33.80, up 0.87% today, showing strong momentum with seven consecutive quarters of earnings beats. The stock exhibits a bullish technical setup with moving averages supporting the uptrend, though RSI levels suggest potential overbought conditions. Revenue growth accelerated to $1.3 billion in 2025 with improving margins, while analyst consensus remains strongly positive with 76% buy ratings and a $37.09 price target. Recent expansion into the UK market and AI platform adoption continue to drive investor optimism.
ZETA presents a compelling growth story with accelerating revenue and expanding customer base, though negative net margins and elevated valuation multiples warrant caution. The stock's proximity to 52-week highs combined with strong institutional support suggests continued upside potential, but investors should monitor margin improvement and competitive pressures in the AI marketing technology space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →